Shares of Celgene (CELG) are on the rise after the company announced that it has agreed to be acquired by Bristol-Myers Squibb (BMY) in a cash and stock transaction with an equity value of about $74B, or $102. 43 a share… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2843327/-Alexion-Biogen-seen-as-potential-targets-after-Celgene-buyout)
previous post
next post